Company intelligence / Profile preview

BioSkryb Genomics

Durham, North Carolina, United Statesbioskryb.com ↗

Ownership: Private
Employees: ~80
Development stage: Commercial

Overview

BioSkryb Genomics has developed proprietary single-cell genomic and transcriptomic amplification technologies, including PTA, ResolveDNA®, and ResolveOME™, enabling high-fidelity whole genome and multiomic analyses from individual cells. These tools are used globally by researchers to study cellular heterogeneity in health and disease, with applications spanning cancer biology, somatic evolution, translational medicine, and diagnostics. The company is not a drug developer but supports clinical/translational research through its commercial products.

Modalities: DeviceService
Industry: Molecular Diagnostics

Partnerships

Ultima GenomicsBIOKÉ/Cell Signaling TechnologyALS Automated Lab Solutions GmbHHuman Cell Atlas project

Beyond the preview

Go deeper on BioSkryb Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSkryb Genomics.

Explore the full profile